Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
H. Lasolle, A. A. Schiavo, A. Tourneur…·M. Romitti
This study uses thyroid organoids to show that combining MAPK and PI3K inhibitors can reverse dedifferentiation in Braf-mutated thyroid cancer cells.